Variation in the Thyrotropic Activity of Human Chorionic Gonadotropin in Chinese Hamster Ovary Cells Arises from Differential Expression of the Human Thyrotropin Receptor and Microheterogeneity of the Hormone

R. HOERMANN, S. POERTL, I. LISS, S. M. AMIR, AND K. MANN

Division of Endocrinology, Department of Medicine, University of Essen, D-45122 Essen; and Medical Department II, Klinikum Grosshadern, University of Munich (S.P., I.L.), D-81377 Munich, Germany; and the Division of Research Grants, National Institutes of Health (S.M.A.), Bethesda, Maryland 20892

ABSTRACT

The role of hCG as a stimulator of the human thyroid has been a subject of controversy, because discrepant results have been obtained in different in vitro assays. In an attempt to explain the variation observed in the thyroid response to hCG, we investigated the ability of hCG and that of its isoforms and glycosylation variants to inhibit [125I]hTSH binding and stimulate adenylate cyclase in two clones, JPO9 and JP26, of Chinese hamster ovary cells stably transfected with the human TSH receptor (hTSHr). The two clones differ with respect to the number of hTSHr expressed per cell (34,000 in JPO9 and 2,000 in JP26 cells). Both responded extremely well to bTSH; the cAMP response to 0.001 IU/L bTSH was distinguishable from basal values. Interestingly, JPO9 cells were readily stimulated by hCG (20–100 mg/L; 0.52–2.6 × 10−6 mol/L) to release cAMP, whereas JP26 cells showed little if any response. Also, cAMP stimulation produced by asialo-hCG was 12-fold in JPO9 cells and only 4-fold in JP26 cells compared to 45- and 67-fold stimulations by bTSH, respectively. Stimulation by asialo-hCG was approximately 30% that of hTSH in JPO9 cells, but less than 6% in JP26 cells. When assessing the thyrotropic activity of the microheterogeneous isoforms of hCG, more alkaline pl forms were found to be more active than those of a more acidic pl regardless of whether they were derived from normal or molar pregnancy urine. Further studies with hCG, asialo-hCG, asialoagalacto-hCG, and deglycosylated hCG revealed that removal of sialic acid caused a marked increase in both its affinity for hTSHr and its cAMP-releasing potency, whereas removal of further carbohydrate, although it slightly enhanced receptor binding, was detrimental to adenylate cyclase activation.

In conclusion, differences in hTSHr expression may cause a variation in the cAMP response to hCG or its glycosylation variants, as does the microheterogeneity of the hormone itself. These mechanisms may be responsible at least in part for the divergent responses of different cell types to hCG and render interpretation of the physiological meaning of the data obtained in recombinant receptor systems difficult. (J Clin Endocrinol Metab 80: 1605-1610, 1995)

hCG exhibits considerable homology in its structure with human TSH (hTSH) as does CG/LH receptor with TSH receptor (TSHr) (1–3). As a result, this hormone has been reported to possess significant thyrotropic activity, which may be clinically relevant in hyperthyroidism of pregnant women and patients with trophoblastic tumors (4). However, its role as a thyroid stimulator has been a subject of controversy, because discrepant results have been obtained in different cell types to hCG and render interpretation of the physiological meaning of the data obtained in recombinant receptor systems difficult. (J Clin Endocrinol Metab 80: 1605–1610, 1995)

Materials and Methods

Materials

Labeled bTSH was purchased from Henning (Berlin, Germany), and the unlabeled hormone (~30 IU/mg) was obtained from Armour Co. (North Chicago, IL). Crude urinary pregnancy hCG (~2500 IU/mg) was obtained from Ayerst (Rouses Point, NY). Highly purified hCG (CR123), used for standardization, was supplied by the Hormone Distribution Program of the NIDDK (Bethesda, MD). Immobilized neuraminidase from Clostridium perfringens (type VI-A) and β-galactosidase were purchased from Sigma Chemical Co. (Deisenhofen, Germany); cell culture
Preparation of hCG, hCG isoforms, and carbohydrate-modified variants of hCG

Highly purified hCG (~12,000 IU/mg) was isolated from crude pregnancy hCG by sequential chromatography on columns of DEAE-52 and Sephadex G-100 (Pharmacia, Freiburg, Germany), as described previously (15). Crude molar hCG extracted from the urine of eight euthyroid patients with hydatidiform moles was pooled and purified using the procedure employed for purification of hCG.

The isoforms of hCG were prepared by chromatography of purified pregnancy (hCGp) or molar hCG (hCGm) on a column of Mono S 5/5 (Pharmacia, Freiburg, Germany), combining the fractions eluted into three pools (pools I-III). The pools were shown by isoelectric focusing to comprise p1 forms of hCG ranging from 3.9-4.1 (pool I), 4.1-5 (pool II), and greater than 5 (pool III). To obtain asialo-hCG, purified hCG was desialylated by digestion with neuraminidase, following the protocol of van Hall et al. (16), which had been previously employed in our laboratory (11, 15, 17). Asialogalacto-hCG was obtained by further enzymatic digestion of asialo-hCG with β-galactosidase (17). hCG lacking almost all of its carbohydrate moity (deglycosylated hCG) was prepared by treating hCG with anhydrous hydrogen fluoride, as described in detail previously (18).

To define its purity and other properties, the hCG preparations were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (under reducing and nonreducing conditions) and analyses of their amino acid composition and contents of sialic acid, galactose, and lacto-hCG was obtained by further enzymatic digestion of asialo-hCG with S-galactosidase (17). hCG lacking almost all of its carbohydrate moity (deglycosylated hCG) was prepared by treating hCG with anhydrous hydrogen fluoride, as described in detail (18).

Results

Characterization of the CHO-TSHr cell clones JP09 and JP26

We compared bTSH binding and cAMP production in the CHO wild-type cells and the CHO-TSHr cell clones, JP26 and JP09. Specific [125]IbTSH binding was less than 1% to CHO cells, 5-7% to JP26 cells, and 26-30% to JP09 cells. Displacement by increasing concentrations of unlabeled bTSH and Scatchard analysis of the data revealed that JP09 cells had a much higher TSH-binding capacity than JP26 cells (Fig. 1a). The difference in the binding capacity of the clones was apparently related to the number of hTSHr expressed per cell, which was estimated to be 34,000 in JP09 and 2,000 in JP26 cells (Fig. 1a). Basal cAMP activity and TSH-stimulated cAMP production were higher in JP09 cells than in JP26 cells. The ratio of maximum bTSH stimulation to basal activity, however, was lower in JP09 than in JP26 cells (~45 vs. 67; Fig. 1b).

Responses of the CHO-TSHr cell clones JP09 and JP26 to hCG and asialo-hCG

We assessed the inhibition of [125]IbTSH binding to CHO-TSHr JP09 and JP26 cells by hCG and asialo-hCG. Although hCG itself displayed little binding-inhibiting activity in either cell clone, asialo-hCG was much more potent in this respect; its ID50 was 20 mg/L (5.8 × 10^-7 mol/L) in JP09 cells and 7 mg/L (2.0 × 10^-7 mol/L) in JP26 cells (Fig. 2a). With respect to cAMP activation, a significant (p < 0.01, combined data from three closely concuring experiments with triplicate determinations), although not very impressive, cAMP increase over basal values in response to hCG stimulation was observed in JP09 cells, whereas little if any stimulation was seen in JP26 cells (Fig. 2b). The difference in the response of the two clones was more pronounced when cells were stimulated with asialo-hCG (Fig. 2b). Asialo-hCG stimulated from total binding to yield specific binding values, which are shown in the figures.
THYROTROPIC ACTIVITY OF hCG IN CHO-TSHr CELLS

FIG. 1. bTSH binding (a; Scatchard plots) and cAMP stimulation by bTSH (b) in two different clones, JPO9 and JP26, of CHO cells expressing hTSHr. JPO9 cells displayed a markedly higher binding capacity than JP26 cells. Because cell number, DNA content, amount of protein, and affinity for hTSHr were comparable in these experiments, the difference in binding capacity was attributable to the number of hTSHr expressed per cell. This was estimated to be 34,000 in JPO9 and 2,000 in JP26 cells. The inset shows the plot for JP26 cells with an expanded scale. Consistent with their increased receptor number, CAMP production was higher in JPO9 cells. The ratio of basal to bTSH-stimulated values, however, was higher in JP26 cells. The values shown represent the means of closely concuring duplicate determinations for specific bTSH binding and the mean ± SD (n = 3) for CAMP determinations. The marked differences between the two cell clones shown here have been a constant finding in three separate experiments.

JP09 cells up to 12-fold and JP26 cells 4-fold over basal values. For comparison, maximum bTSH stimulation in the same experiment was 45-fold in JP09 cells and 67-fold in JP26 cells. Maximum stimulation by asialo-hCG amounted to 30% of that induced by bTSH in JP09 cells. The ratio of basal to bTSH-stimulated values, however, was higher in JP26 cells. The values shown represent the means of closely concurring duplicate determinations for specific [125I]bTSH binding and the mean ± SD (n = 3) for CAMP determinations. The marked differences between the two cell clones shown here have been a constant finding in three separate experiments.

Thyrotropic activity of hCG isoforms in CHO-TSHr cells

Next, the in vitro thyrotropic potencies of hCG isoforms derived from pregnancy and molar hCG were assessed in CHO-TSHr JP09 cells. Pool II (pI 4.1–5) and pool III (pI >5) derived from hCGp were more active than pool I (pI 3.9–4.1) of hCGp in terms of the ability to both inhibit [125I]bTSH binding and stimulate cAMP production (Fig. 3). Similarly, in the pools obtained from hCGm, a more alkaline pI was associated with increased thyrotropic activity (Fig. 3). When comparing hCGp and hCGm, on the other hand, the presence of alkaline isoforms was about the same in the two preparations (Fig. 3, inset), and the CAMP-stimulating activity in CHO-TSHr cells was also similar (data not shown). The corresponding pools derived from hCGp or hCGm also did not differ in potency to bind to and stimulate CAMP release from CHO-TSHr cells (Fig. 3).

Role of carbohydrate in hCG for hTSHr binding and CAMP stimulation in CHO-TSHr cells

The immunological activities of hCG, asialo-hCG, asialo-galacto-hCG, and deglycosylated hCG preparations employed in these studies were assessed by a specific holo-hCG assay and found to be comparable (data not shown). As shown earlier, hCG itself showed little ability to inhibit [125I]bTSH binding to CHO-TSHr cells (JP09), and desialylation of hCG resulted in a marked enhancement of its activity. Removal of additional galactose residues, on the other hand, caused only a minor increase in the affinity of hTSHr
FIG. 3. Inhibition of $^{[125]}$I-bTSH binding (a) and stimulation of cAMP activity (b) in CHO-TSHr JPO9 cells by hCG isoforms derived from pregnancy (hCGp) or molar hCG (hCGm). The isoforms contained in hCGp and hCGm were visualized by isoelectric focusing (see inset) and fractionated into three pools by cation exchange chromatography: pool I comprising the p1 forms from pI 3.9–4.1, pool II from pI 4.1–5.0, and pool III with pI above 5.0. The indices p and m indicate the origin of the pool from either hCGp or hCGm. The thyrotropic activities of the pools appear to be related to their pI values, but unrelated to their origin from hCGp or hCGm. The values shown represent the means of closely concurring duplicates for specific binding data and the mean ± SD (n = 3) for CAMP determinations. The differences in $^{[125]}$I-bTSH binding inhibition and CAMP stimulatory activity between the pools shown were the same as those observed in two other experiments.

FIG. 4. Inhibition of $^{[125]}$I-bTSH binding (a) and stimulation of cAMP activity (b) in CHO-TSHr JPO9 cells by the hCG variants asialo-hCG, asialoagalacto-hCG, and deglycosylated hCG. Removal of sialic acid from hCG markedly enhances both the affinity to hTSHr and the intrinsic activity of the hormone, whereas removal of further carbohydrates, although slightly favoring receptor binding, impairs receptor activation. At the maximum concentration tested (100 IU/L), bTSH released 1600 nmol/L CAMP (not shown). Each point represents the mean of closely concurring duplicates for specific binding data and the mean ± SD (n = 3) for CAMP determinations in a single experiment, and the results concur closely with those obtained in two other experiments.

Discussion

The occurrence of hyperthyroidism in patients with trophoblastic tumors and some cases of normal pregnancy may be explained by stimulation of the thyroid gland by hCG, which is present in exceedingly high concentrations in the circulation of these patients; a distinct molecular variant form of hCG with increased thyrotropic activity produced by the trophoblastic tumor or during pregnancy; or a combination of the two factors (7). With respect to the in vitro thyrotropic activity of hCG, most investigators were unable to demonstrate significant stimulation of the cAMP response in human thyroid membranes (8–10, 15). The same failure to stimulate cAMP activity in vitro has been observed in a human thyroid carcinoma cell line (HTC) expressing the recombinant hTSHr, but lacking endogenous hTSHr (11). In thyroid cells of rodent origin, on the other hand, including FRTL-5 cells and CHO cells transfected with the hTSHr, hCG has been shown to readily evoke significant cAMP responses (10, 18, 26–30). Clearly, the discrepancies seemed too pronounced to be explained by the use of different assay conditions.

To seek possible explanations for the variation observed in the thyroid response to hCG, we studied two clones of CHO cells that had been stably transfected with hTSHr.
ably, the cAMP responses to hCG and its variant form asialo-hCG differed widely between the two clones. Although clone JP26 showed little, if any, response, clone JP09 was readily stimulated by hCG to release cAMP, with 1 IU of the hormone displaying a potency equivalent to \(5 \times 10^{-4}\) IU bTSH. A similar thyrotropic activity of hCG has recently been reported by Yoshimura et al. (30), who used the same cell line. The difference between the two cell clones in their response to asialo-hCG, which was a more potent stimulator than hCG, was even more striking. Interestingly, in our studies, the hCG responsiveness of the two CHO cell clones appeared not to parallel their bTSH sensitivity. This conclusion was further supported by the finding that cAMP production by asialo-hCG approached 30% that of bTSH in JP09 cells, but less than 6% that in JP26 cells. Both clones were extremely sensitive to stimulation by bTSH, with a response induced by a concentration as low as 0.001 IU/L (0.89 pmol/L) being readily distinguishable from basal activity. For comparison, in HTC-TSHr cells, the limit of detection was about 0.1 IU/1. bTSH (11). The variation observed in the responses to the various stimulators of the two CHO cell clones expressing hTSHr was surprising. It may be accounted for by differences in the expression of hTSHr in the two clones. In this respect, the binding studies we conducted indicated a number of hTSHr per cell in the physiological range in JP26 cells, whereas hTSHr density in JP09 cells was more than 10 times higher than that in normal human thyrocytes (31). The possibility that cAMP stimulation was affected in part by a stimulation of endogenous hCG/LH receptors could be excluded, because CHO wild-type cells were not stimulated by hCG or asialo-hCG.

Another interesting aspect of the study relates to the role of carbohydrate in the thyrotropic activity of hCG in CHO-TSHr cells, which was strikingly different from that previously reported in human assay systems. In human thyroid membranes or cells, including HTC cells expressing hTSHr (32), desialylated variants of hCG, although exhibiting markedly increased affinity for hTSHr, were devoid of intrinsic activity and acted as pure antagonists (11, 15, 17, 33, 34). In contrast, in CHO-TSHr cells, desialylation of hCG resulted in a marked increase in both its affinity for hTSHr and its cAMP-stimulating activity. This was true for less sialylated isoforms of hCG and enzymatically desialylated hCG. Also, the effect was more pronounced in JP09 cells, which express an exceedingly high receptor density, than in JP26 cells. Cleavage of further carbohydrate, such as galactose, and removal of nearly the total carbohydrate moiety, on the other hand, although slightly improving receptor recognition, exerted a detrimental influence on intrinsic activity in JP09 cells, although asialo-galacto-hCG and deglycosylated hCG were still more active than hCG. Interestingly, JP09 cells closely resemble FRTL-5 cells in this respect, which we have previously shown to be stimulated by desialylated hCG variants (18).

Consistent with these findings, the rodent thyroid has long been recognized to be more sensitive to stimulation by hCG and desialylated hCG than the human thyroid (10, 26). Apparently, the role of carbohydrate in signal transduction varies among cells that differentially express TSHr or different types of cells expressing TSHr. This may explain at least in part the divergent responses to carbohydrate-modified hCG forms observed in various cell lines. As for the CHO cells expressing hTSHr, although they provide one of the most sensitive tools currently available for measuring thyroid stimulators, their nonthyroid nonhuman descent and the supraphysiological hTSHr number expressed emphasize the fact that any conclusions about the physiological significance of the findings derived from CHO cells should be drawn with caution. For that reason, at the present time it is not possible to resolve, on the basis of these studies, the ongoing controversy of whether hCG is indeed a thyroid stimulator of significant potency in man. The present findings provide a strong support in favor of the use of human thyroid cell lines, such as HTC, for hTSHr expression studies.

With respect to the existence of molecular forms of hCG with increased thyrotropic activity, the present study revealed a variation in thyrotropic activity among the microheterogeneous isoforms of hCG (35, 36). It is important to note that this study, unlike previous studies by Pekary et al. (37) and Yoshimura et al. (38), focused on the isoforms of hCG and did not include variant forms of hCG or fragments thereof, which are known to be present in pregnancy urine or placental tissue extracts. These researchers reported an increased in vitro thyrotropic activity of partially sialated hCG variants extracted from hydatidiform moles of hyperthyroid patients (37). In contrast to their material, our molar hCG was derived from euthyroid patients. The present study revealed a relation between the pi value of the hCG molecules and their thyrotropic activity in CHO-TSHr JP09 cells, with alkaline isoforms displaying an enhanced potency. This was true for hCG of both pregnancy and molar origin. On the other hand, we found no major differences between the activities of molar hCG and pregnancy hCG or between the isoforms of identical pi derived from hCG or hCGm. We conclude that, apart from tumor-derived hCG variants, which may be either highly acidic or basic forms of hCG (37-39), the hCG molecule itself is made up of isohormones that differ in their thyrotropic activity, and even subtle changes in the pi spectrum of hCG may affect its thyrotropic activity.

In conclusion, both the differential expression of hTSHr and the intrinsic microheterogeneity of the hormone cause a variation in the cAMP response to hCG in CHO-TSHr cells. Both mechanisms may at least in part explain previous observations that the hCG response differs among thyroid cells, particularly when they are derived from different species, and that the correlation between serum hCG concentrations and thyroid hormone levels in patients with trophoblast disease has been generally found to be poor (10, 39-42). They may also play a role in modulating the thyroid response to hCG during pregnancy or trophoblast disease.

References

4. Hershman JM. 1991 Hyperthyroidism caused by trophoblastic tu-


15. Hoermann R, Amir SM, Inghar SH. 1988 Evidence that partially desialylated variants of human chorionic gonadotropin (hCG) are the factors in crude hCG that inhibit the response to thyrotropin in human thyroid membranes. Endocrinology. 120:1535–1543.


